EGFR and non-small cell lung carcinoma: However, various EGFR mutation detection methods were used in studies regarding the efficacy of erlotinib in EGFR-wt NSCLC and their false negative rates have been suspected to be a possible reason for the responses to EGFR-TKIs in patients without detectable EGFR mutations [14], [15].